These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 22661489)

  • 1. Improved neuropsychological and neurological functioning across three antiretroviral regimens in diverse resource-limited settings: AIDS Clinical Trials Group study a5199, the International Neurological Study.
    Robertson K; Jiang H; Kumwenda J; Supparatpinyo K; Evans S; Campbell TB; Price R; Tripathy S; Kumarasamy N; La Rosa A; Santos B; ; Silva MT; Montano S; Kanyama C; Faesen S; Murphy R; Hall C; Marra CM; Marcus C; Berzins B; Allen R; Housseinipour M; Amod F; Sanne I; Hakim J; Walawander A; Nair A;
    Clin Infect Dis; 2012 Sep; 55(6):868-76. PubMed ID: 22661489
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human Immunodeficiency Virus-associated Neurocognitive Impairment in Diverse Resource-limited Settings.
    Robertson KR; Jiang H; Kumwenda J; Supparatpinyo K; Marra CM; Berzins B; Hakim J; Sacktor N; Campbell TB; Schouten J; Mollan K; Tripathy S; Kumarasamy N; La Rosa A; Santos B; Silva MT; Kanyama C; Firhnhaber C; Murphy R; Hall C; Marcus C; Naini L; Masih R; Hosseinipour MC; Mngqibisa R; Badal-Faesen S; Yosief S; Vecchio A; Nair A;
    Clin Infect Dis; 2019 May; 68(10):1733-1738. PubMed ID: 30219843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Change in vitamin d levels occurs early after antiretroviral therapy initiation and depends on treatment regimen in resource-limited settings.
    Havers FP; Detrick B; Cardoso SW; Berendes S; Lama JR; Sugandhavesa P; Mwelase NH; Campbell TB; Gupta A;
    PLoS One; 2014; 9(4):e95164. PubMed ID: 24752177
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human Immunodeficiency Virus Type 1 and Tuberculosis Coinfection in Multinational, Resource-limited Settings: Increased Neurological Dysfunction.
    Robertson KR; Oladeji B; Jiang H; Kumwenda J; Supparatpinyo K; Campbell TB; Hakim J; Tripathy S; Hosseinipour MC; Marra CM; Kumarasamy N; Evans S; Vecchio A; La Rosa A; Santos B; Silva MT; Montano S; Kanyama C; Firnhaber C; Price R; Marcus C; Berzins B; Masih R; Lalloo U; Sanne I; Yosief S; Walawander A; Nair A; Sacktor N; Hall C;
    Clin Infect Dis; 2019 May; 68(10):1739-1746. PubMed ID: 30137250
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of three antiretroviral regimens for initial treatment of HIV-1: a randomized clinical trial in diverse multinational settings.
    Campbell TB; Smeaton LM; Kumarasamy N; Flanigan T; Klingman KL; Firnhaber C; Grinsztejn B; Hosseinipour MC; Kumwenda J; Lalloo U; Riviere C; Sanchez J; Melo M; Supparatpinyo K; Tripathy S; Martinez AI; Nair A; Walawander A; Moran L; Chen Y; Snowden W; Rooney JF; Uy J; Schooley RT; De Gruttola V; Hakim JG;
    PLoS Med; 2012; 9(8):e1001290. PubMed ID: 22936892
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized factorial trial comparing 4 treatment regimens in treatment-naive HIV-infected persons with AIDS and/or a CD4 cell count <200 cells/μL in South Africa.
    ; Ratsela A; Polis M; Dhlomo S; Emery S; Grandits G; Khabo P; Khanyile T; Komati S; Neaton JD; Naidoo LC; Magongoa D; Qolohle D
    J Infect Dis; 2010 Nov; 202(10):1529-37. PubMed ID: 20942650
    [TBL] [Abstract][Full Text] [Related]  

  • 7. International neurocognitive normative study: neurocognitive comparison data in diverse resource-limited settings: AIDS Clinical Trials Group A5271.
    Robertson K; Jiang H; Evans SR; Marra CM; Berzins B; Hakim J; Sacktor N; Silva MT; Campbell TB; Nair A; Schouten J; ; Kumwenda J; Supparatpinyo K; Tripathy S; Kumarasamy N; la Rosa A; Montano S; Mwafongo A; Firnhaber C; Sanne I; Naini L; Amod F; Walawander A;
    J Neurovirol; 2016 Aug; 22(4):472-8. PubMed ID: 26733457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.
    Gallant JE; DeJesus E; Arribas JR; Pozniak AL; Gazzard B; Campo RE; Lu B; McColl D; Chuck S; Enejosa J; Toole JJ; Cheng AK;
    N Engl J Med; 2006 Jan; 354(3):251-60. PubMed ID: 16421366
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune Reconstitution in Severely Immunosuppressed Antiretroviral-Naive HIV-1-Infected Patients Starting Efavirenz, Lopinavir-Ritonavir, or Atazanavir-Ritonavir Plus Tenofovir/Emtricitabine: Final 48-Week Results (The Advanz-3 Trial).
    Miro JM; Manzardo C; Ferrer E; Loncà M; Guardo AC; Podzamczer D; Domingo P; Curran A; Clotet B; Cruceta A; Lozano F; Pérez I; Plana M; Gatell JM;
    J Acquir Immune Defic Syndr; 2015 Jun; 69(2):206-15. PubMed ID: 25831464
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuropsychological functioning and antiretroviral treatment in HIV/AIDS: a review.
    Cysique LA; Brew BJ
    Neuropsychol Rev; 2009 Jun; 19(2):169-85. PubMed ID: 19424802
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased virological failure in naive HIV-1-infected patients taking lamivudine compared with emtricitabine in combination with tenofovir and efavirenz or nevirapine in the Dutch nationwide ATHENA cohort.
    Rokx C; Fibriani A; van de Vijver DA; Verbon A; Schutten M; Gras L; Rijnders BJ;
    Clin Infect Dis; 2015 Jan; 60(1):143-53. PubMed ID: 25273080
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does choice of combination antiretroviral therapy (cART) alter changes in cerebral function testing after 48 weeks in treatment-naive, HIV-1-infected individuals commencing cART? A randomized, controlled study.
    Winston A; Duncombe C; Li PC; Gill JM; Kerr SJ; Puls R; Petoumenos K; Taylor-Robinson SD; Emery S; Cooper DA;
    Clin Infect Dis; 2010 Mar; 50(6):920-9. PubMed ID: 20146627
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial.
    Venter WDF; Sokhela S; Simmons B; Moorhouse M; Fairlie L; Mashabane N; Serenata C; Akpomiemie G; Masenya M; Qavi A; Chandiwana N; McCann K; Norris S; Chersich M; Maartens G; Lalla-Edward S; Vos A; Clayden P; Abrams E; Arulappan N; Hill A
    Lancet HIV; 2020 Oct; 7(10):e666-e676. PubMed ID: 33010240
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neurocognitive effects of treatment interruption in stable HIV-positive patients in an observational cohort.
    Robertson KR; Su Z; Margolis DM; Krambrink A; Havlir DV; Evans S; Skiest DJ;
    Neurology; 2010 Apr; 74(16):1260-6. PubMed ID: 20237308
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predicting HIV disease progression in children using measures of neuropsychological and neurological functioning. Pediatric AIDS clinical trials 152 study team.
    Pearson DA; McGrath NM; Nozyce M; Nichols SL; Raskino C; Brouwers P; Lifschitz MC; Baker CJ; Englund JA
    Pediatrics; 2000 Dec; 106(6):E76. PubMed ID: 11099619
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A multinational study of neurological performance in antiretroviral therapy-naïve HIV-1-infected persons in diverse resource-constrained settings.
    Robertson K; Kumwenda J; Supparatpinyo K; Jiang JH; Evans S; Campbell TB; Price RW; Murphy R; Hall C; Marra CM; Marcus C; Berzins B; Masih R; Santos B; Silva MT; Kumarasamy N; Walawander A; Nair A; Tripathy S; Kanyama C; Hosseinipour M; Montano S; La Rosa A; Amod F; Sanne I; Firnhaber C; Hakim J; Brouwers P;
    J Neurovirol; 2011 Oct; 17(5):438-47. PubMed ID: 21786076
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacogenetics of unboosted atazanavir in HIV-infected individuals in resource-limited settings: a sub-study of the AIDS Clinical Trials Group (ACTG) PEARLS study (NWCS 342).
    Castillo-Mancilla JR; Aquilante CL; Wempe MF; Smeaton LM; Firnhaber C; LaRosa AM; Kumarasamy N; Andrade A; Baheti G; Fletcher CV; Campbell TB; Haas DW; MaWhinney S; Anderson PL
    J Antimicrob Chemother; 2016 Jun; 71(6):1609-18. PubMed ID: 26892777
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Associations of inflammatory markers with AIDS and non-AIDS clinical events after initiation of antiretroviral therapy: AIDS clinical trials group A5224s, a substudy of ACTG A5202.
    McComsey GA; Kitch D; Sax PE; Tierney C; Jahed NC; Melbourne K; Ha B; Brown TT; Bloom A; Fedarko N; Daar ES
    J Acquir Immune Defic Syndr; 2014 Feb; 65(2):167-74. PubMed ID: 24121755
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of advanced AIDS-associated Kaposi sarcoma in resource-limited settings: a three-arm, open-label, randomised, non-inferiority trial.
    Krown SE; Moser CB; MacPhail P; Matining RM; Godfrey C; Caruso SR; Hosseinipour MC; Samaneka W; Nyirenda M; Busakhala NW; Okuku FM; Kosgei J; Hoagland B; Mwelase N; Oliver VO; Burger H; Mngqibisa R; Nokta M; Campbell TB; Borok MZ;
    Lancet; 2020 Apr; 395(10231):1195-1207. PubMed ID: 32145827
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials.
    Cahn P; Madero JS; Arribas JR; Antinori A; Ortiz R; Clarke AE; Hung CC; Rockstroh JK; Girard PM; Sievers J; Man C; Currie A; Underwood M; Tenorio AR; Pappa K; Wynne B; Fettiplace A; Gartland M; Aboud M; Smith K;
    Lancet; 2019 Jan; 393(10167):143-155. PubMed ID: 30420123
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.